Goldman Sachs predicts more than 50% concentration for these 2 stocks
Shares started this year with big gains, retreating last week and now rising again. The big tech giants led the moves, with volatility in Apple and Amazon leading the NASDAQ in their voltages. Goldman Sachs investment bank’s strategy team has taken heed of market shocks and is working on what it means for investors. According to macro-strategist Gurpreet Gill, looking closely at bond yields and stock values, “the rise in global yields is a reflection of improved growth prospects given the encouraging vaccine progress and the upcoming major fiscal stimulus United States. [It] it also indicates higher inflation expectations and, in turn, pushed ahead with expectations for the timing of monetary policy normalization. ”Monetary policy may be key to calming investors’ concerns and, in this regard, is considered Federal Reserve Chairman Jerome Powell testified in Congress that in his comments to lawmakers, the head of the central bank indicated that the Fed has no intention of raising interest rates anytime soon. prospects fit in with the predictions of Goldman economist Jan Hatzius, who earlier this year said the Fed would keep rates tight and that 2021 would be a good year for long positions in equities. at the macro perspective.At the micro level, in terms of individual stocks, Goldman analysts have been busy locating stocks that they believe will gain if current conditions are maintained in the short to medium term. shares in particular with, in their opinion, a bullish potential of 50% or higher. Using the TipRanks database, we found that both tickers also have a consensual “Strong Buy” rating for the rest of the street. Vinci Partners Investments (VINP) The first Goldman option we are studying is Vinci Partners, an alternative investment and asset management company based in Brazil. The company offers its clients a wide range of services and funds, including access to hedge funds, real estate and infrastructure investments, private equity investments and credit investments. Vinci has a global reach and a leading position in the Brazilian wealth management industry. To kick off the new year, Vinci went public on the NASDAQ index. Shares of VINP began trading on January 28 at $ 17.70, slightly below the company’s initial $ 18 price. On the first day of trading, 13.87 million VINP shares went on sale. After about 4 weeks in the public markets, Vinci has a market cap of $ 910 million. Covering these stocks by Goldman Sachs, analyst Tito Labarta describes Vinci as a well-diversified asset platform with strong growth potential. “We believe that Vinci is well positioned to win shares and overcome market growth given strong competitive advantages. Vinci has one of the most diverse product offerings among its alternative asset management partners, with seven different investment strategies and 261 funds. In addition, Vinci has surpassed its benchmarks in all strategies, has had a solid track record and has been recognized with awards from relevant institutions such as Institutional Investor, Morningstar, Exame and InfoMoney. The company has developed strong communication tools to strengthen its institutional and brand presence in the Brazilian market, such as podcasts, seminars, investor conferences with IFA, among other participations in events and webinars “, said Labarta. its optimistic outlook, Labarta values VINP for purchase, and its $ 39 price target implies an impressive 141% upside potential for next year ((To see Labarta’s trajectory, click here). A month on the NASDAQ has drawn positive attention from Vinci by Wall Street analysts, with 3%) to 1 division in reviews that favor purchases above withholdings and give the stock the consensus rating of the Strong Buy analyst.The stock is currently selling for $ 16.15 and its average price of $ 26.75 suggests that it has room for ~ 66% growth over the next 12 months. (See Analysis of VINP values in TipRanks) Ortho Clinical Diagn ostics Holdings (OCDX) Goldman Sachs analysts have also pointed to Ortho Clinical Diagnostics as a potential winner for investors. , a leader in the field of in vitro diagnostics, works with hospitals, clinics, laboratories and blood banks around the world to deliver fast, safe and accurate test results. Ortho Clinical Diagnostics has several important “firsts” in its industry: it was the first company to present a diagnostic test for the detection of Rh +/- blood, for the detection of HIV and HEP-C antibodies, and more has recently been working on COVID- 19 tests. Ortho is the world’s largest in vitro diagnostic company, performing more than a million daily tests on more than 800,000 patients worldwide. Like Vinci Partners previously, this company went public on January 28th. The IPO saw Ortho put 76 million shares on the market, with trading on the first day at $ 15.50, below initial prices of $ 17. However, the IPO raised $ 1.2 trillion in gross funds and the option to over-allocate insurers contributed an additional $ 193 million. Goldman Sachs analyst Matthew Sykes believes the company’s past growth performance justifies a positive sentiment and that Ortho is able to offset its balance sheet. “The key to the history of equity for OCDX is to successfully restore its organic growth rate to a lasting 5-7% from an approximately flat historical rate. Given the level of profitability and potential generation of FCF , if OCDX restores growth, they could reduce the balance sheet and increase their level of inorganic and organic investments to create a sustainable growth algorithm, ”Sykes wrote. The analyst added: “Our key growth factor is the increase in OCDD’s lifetime customer value driven by a transition in the product set of its clinical laboratory business from a clinical chemistry instrument independent to an integrated platform and finally to an automated platform This transition occurs largely within its own customer base, so it does not depend on the displacement, but serves the need to increase the performance of the a client’s diagnostic capabilities.To this end, Sykes values OCDX as a purchase and sets a price of $ 27. Target.At current levels, this implies a 51% one-year increase. from Sykes, click here) Ortho has a long history of getting results for its clients, and this puts Wall Street in a valuing mood.OCDX shares get a strong buy from the consensus of analysts, based on reviews of 9 established purchases from the IPO, against a single withholding. The average price target is $ 23.80, which indicates 33% of the current trading price of $ 17.83. (See OCDX stock analysis in TipRanks) To find good ideas for trading stocks with attractive valuations, visit TipRanks’ Best Stocks to Buy, a recently launched tool that brings together all the knowledge about TipRanks equities. Disclaimer: The views expressed in this article are solely those of leading analysts. The content is intended for informational purposes only. It is very important to do your own analysis before making any investment.